Urothelial Carcinoma - Epidemiology Forecast - 2034
Description
Key Highlights
Urothelial Carcinoma is a type of cancer that originates in urothelial cells, which form the lining of the urinary tract known as the urothelium. This cancer can occur in either the upper part of the urinary tract, such as the renal pelvis and ureter, or in the lower part, including the bladder and urethra.
Approximately ~90% of Urothelial Carcinoma are Urothelial bladder cancer (UBC), whereas upper tract urothelial carcinoma (UTUC) accounts for just ~10% of all urothelial malignancies.
It is a cancer that predominately affects males, although this could be related to the fact that the prevalence of smoking is much higher among males than females, which is a major risk factor for UCC.
In 2024, the United States led the 7MM in incident urothelial carcinoma (UCC) cases, reflecting its large population base and potential environmental or lifestyle-related risk factors contributing to disease burden.
The majority of new UC diagnoses in the US occurred in individuals aged 80 and above, highlighting a strong age-related predisposition and the growing need for tailored treatment approaches in elderly populations.
Males represented nearly 75% of incident UC cases across the 7MM in 2024, emphasizing a persistent gender disparity likely driven by differences in risk exposures such as smoking and occupational hazards.
In the 7MM, non-muscle invasive UCC accounted for approximately 140 thousand cases, while muscle invasive UCC comprised 75 thousand cases in 2024.
Overall, the UCC landscape in the 7MM shows a higher incidence in older adults, with the greatest burden observed in the US—underscoring the need for focused screening, biomarker-based approaches, and age-specific treatment strategies.
DelveInsight’s “Urothelial Carcinoma (UCC) report delivers an in-depth understanding of UCC historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Urothelial Carcinoma (UCC) Disease Understanding
Urothelial Carcinoma (UCC) Overview, and Diagnosis
UCC, also known as transitional cell carcinoma, is a type of cancer that originates in the urothelial cells lining the bladder, urethra, ureters, renal pelvis, and certain other organs. The vast majority of bladder cancers fall under this category.
UCC is the invasion of the basement membrane or lamina propria by neoplastic cells of urothelial origin. Approximately all cases of UCC are UBC (90%), whereas UTUC accounts for just 5–10% of all urothelial malignancies. The main causative agents of upper tract urothelial carcinoma (UTUC) and urinary bladder cancer (UBC) include cigarette smoking and work-related exposure, along with certain other risk factors.
Out of seven available tests, six have received FDA approval, while one complies with the standards set by the Clinical Laboratory Improvement Act. Among these, NMP22, NMP22 Bladder Check, and UroVysion are FDA-approved for both diagnosis and monitoring of bladder cancer (BC), whereas immunohistology (uCyt+), BTA-TRAK, and BTA-STAT are approved solely for surveillance purposes.
The gold standard for bladder cancer detection remains urine cytology and cystoscopy. Urine cytopathology is a commonly used, noninvasive method for diagnosing and monitoring BC. Although urine cytology offers high specificity, its sensitivity is low, especially for detecting low-grade tumors, and its diagnostic reliability often depends on the expertise of the cytopathologist.
Urothelial Carcinoma (UCC) Epidemiology
The UCC epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by tumor location, Gender-specific cases, Age-specific cases, Mutation-specific cases, and Stage-specific cases in the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
In 2024, the United States reported approximately 40,000 incident cases of TP53-mutated UCC, highlighting the clinical importance of biomarker-driven stratification in guiding therapeutic decisions and prognosis in the United States population.
Among the EU4 and the UK, Germany accounted for the highest number of newly diagnosed UCC cases in 2024, representing nearly 32% of the region’s total burden. This concentration emphasizes Germany’s significant share of UCC diagnoses across EU4 and the UK.
Japan contributed approximately 23,000 incident cases of urothelial carcinoma in 2024, underscoring the ongoing cancer burden in the country and the importance of tailored treatment strategies within its aging population.
Age-based analysis in the United States in 2024 revealed that individuals under 50 years old accounted for the lowest number of new UCC cases in 2024—approximately 1,800 reinforcing the strong age-dependent nature of disease onset.
In 2024, males made up the majority—approximately 73%—of all incident UCC cases across the EU4 and the UK. This showed a marked male dominance in UCC incident cases.
KOL Views
To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease incidence.
DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Johns Hopkins Hospital, USA, US; University Medicine Essen - Ruhrlandklinik, Germany; Institut Curi, France; Università Politecnica delle Marche Home, Italy; Arnau de Vilanova University Hospital, Spain; The Institute of Cancer Research, UK; The National Cancer Center Tokyo, Japan and others were contacted. Their opinion helps understand and validate current disease incidence, gender involved with the disease, diagnosis rate, and diagnostic criteria.
Scope of the Report
The report covers a segment of key events, an executive summary, and a descriptive overview of UCC explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.
Urothelial Carcinoma (UCC) Report Insights
Patient Population
Country-wise Epidemiology Distribution
Urothelial Carcinoma (UCC) Report Key Strengths
Ten-year Forecast
The 7MM Coverage
UCC Epidemiology Segmentation
Urothelial Carcinoma (UCC) Report Assessment
Epidemiology Segmentation
Current Diagnostic Practices
FAQs
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of UCC?
What will be the growth opportunities across the 7MM with respect to the patient population pertaining to UCC?
What is the historical and forecasted UCC patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What is the diagnostic pattern of UCC?
Which clinical factors will affect UCC?
Which factors will affect the increase in the diagnosis of UCC?
Reasons to buy
Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the change in UCC cases in varying geographies over the coming years.
A detailed overview of Total Incident cases of UCC is included.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Urothelial Carcinoma is a type of cancer that originates in urothelial cells, which form the lining of the urinary tract known as the urothelium. This cancer can occur in either the upper part of the urinary tract, such as the renal pelvis and ureter, or in the lower part, including the bladder and urethra.
Approximately ~90% of Urothelial Carcinoma are Urothelial bladder cancer (UBC), whereas upper tract urothelial carcinoma (UTUC) accounts for just ~10% of all urothelial malignancies.
It is a cancer that predominately affects males, although this could be related to the fact that the prevalence of smoking is much higher among males than females, which is a major risk factor for UCC.
In 2024, the United States led the 7MM in incident urothelial carcinoma (UCC) cases, reflecting its large population base and potential environmental or lifestyle-related risk factors contributing to disease burden.
The majority of new UC diagnoses in the US occurred in individuals aged 80 and above, highlighting a strong age-related predisposition and the growing need for tailored treatment approaches in elderly populations.
Males represented nearly 75% of incident UC cases across the 7MM in 2024, emphasizing a persistent gender disparity likely driven by differences in risk exposures such as smoking and occupational hazards.
In the 7MM, non-muscle invasive UCC accounted for approximately 140 thousand cases, while muscle invasive UCC comprised 75 thousand cases in 2024.
Overall, the UCC landscape in the 7MM shows a higher incidence in older adults, with the greatest burden observed in the US—underscoring the need for focused screening, biomarker-based approaches, and age-specific treatment strategies.
DelveInsight’s “Urothelial Carcinoma (UCC) report delivers an in-depth understanding of UCC historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Urothelial Carcinoma (UCC) Disease Understanding
Urothelial Carcinoma (UCC) Overview, and Diagnosis
UCC, also known as transitional cell carcinoma, is a type of cancer that originates in the urothelial cells lining the bladder, urethra, ureters, renal pelvis, and certain other organs. The vast majority of bladder cancers fall under this category.
UCC is the invasion of the basement membrane or lamina propria by neoplastic cells of urothelial origin. Approximately all cases of UCC are UBC (90%), whereas UTUC accounts for just 5–10% of all urothelial malignancies. The main causative agents of upper tract urothelial carcinoma (UTUC) and urinary bladder cancer (UBC) include cigarette smoking and work-related exposure, along with certain other risk factors.
Out of seven available tests, six have received FDA approval, while one complies with the standards set by the Clinical Laboratory Improvement Act. Among these, NMP22, NMP22 Bladder Check, and UroVysion are FDA-approved for both diagnosis and monitoring of bladder cancer (BC), whereas immunohistology (uCyt+), BTA-TRAK, and BTA-STAT are approved solely for surveillance purposes.
The gold standard for bladder cancer detection remains urine cytology and cystoscopy. Urine cytopathology is a commonly used, noninvasive method for diagnosing and monitoring BC. Although urine cytology offers high specificity, its sensitivity is low, especially for detecting low-grade tumors, and its diagnostic reliability often depends on the expertise of the cytopathologist.
Urothelial Carcinoma (UCC) Epidemiology
The UCC epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by tumor location, Gender-specific cases, Age-specific cases, Mutation-specific cases, and Stage-specific cases in the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
In 2024, the United States reported approximately 40,000 incident cases of TP53-mutated UCC, highlighting the clinical importance of biomarker-driven stratification in guiding therapeutic decisions and prognosis in the United States population.
Among the EU4 and the UK, Germany accounted for the highest number of newly diagnosed UCC cases in 2024, representing nearly 32% of the region’s total burden. This concentration emphasizes Germany’s significant share of UCC diagnoses across EU4 and the UK.
Japan contributed approximately 23,000 incident cases of urothelial carcinoma in 2024, underscoring the ongoing cancer burden in the country and the importance of tailored treatment strategies within its aging population.
Age-based analysis in the United States in 2024 revealed that individuals under 50 years old accounted for the lowest number of new UCC cases in 2024—approximately 1,800 reinforcing the strong age-dependent nature of disease onset.
In 2024, males made up the majority—approximately 73%—of all incident UCC cases across the EU4 and the UK. This showed a marked male dominance in UCC incident cases.
KOL Views
To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease incidence.
DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Johns Hopkins Hospital, USA, US; University Medicine Essen - Ruhrlandklinik, Germany; Institut Curi, France; Università Politecnica delle Marche Home, Italy; Arnau de Vilanova University Hospital, Spain; The Institute of Cancer Research, UK; The National Cancer Center Tokyo, Japan and others were contacted. Their opinion helps understand and validate current disease incidence, gender involved with the disease, diagnosis rate, and diagnostic criteria.
Scope of the Report
The report covers a segment of key events, an executive summary, and a descriptive overview of UCC explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.
Urothelial Carcinoma (UCC) Report Insights
Patient Population
Country-wise Epidemiology Distribution
Urothelial Carcinoma (UCC) Report Key Strengths
Ten-year Forecast
The 7MM Coverage
UCC Epidemiology Segmentation
Urothelial Carcinoma (UCC) Report Assessment
Epidemiology Segmentation
Current Diagnostic Practices
FAQs
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of UCC?
What will be the growth opportunities across the 7MM with respect to the patient population pertaining to UCC?
What is the historical and forecasted UCC patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What is the diagnostic pattern of UCC?
Which clinical factors will affect UCC?
Which factors will affect the increase in the diagnosis of UCC?
Reasons to buy
Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the change in UCC cases in varying geographies over the coming years.
A detailed overview of Total Incident cases of UCC is included.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Table of Contents
60 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Urothelial Carcinoma (UCC) Patient Overview at a Glance
- 3.1. Patient Share Distribution (%) in the 7MM in 2024
- 3.2. Patient Share Distribution (%) in the 7MM in 2034
- 4. Executive Summary of UCC
- 6. Epidemiology and Market Forecast Methodology
- 7. Disease Background and Overview
- 7.1. Introduction
- 7.2. Signs and Symptoms
- 7.3. Causes
- 7.4. Diagnosis and Differential Diagnosis
- 7.4.1. Diagnostic Algorithm
- 7.4.2. Differential Diagnosis
- 7.4.3. Diagnostic Guidelines
- 8. Epidemiology and Patient Population
- 8.1. Key Findings
- 8.2. Assumptions and Rationale
- 8.3. Total Incident Cases of UCC in the 7MM
- 8.4. The United States
- 8.4.1. Total Incident Cases of UCC in the United States
- 8.4.2. UCC Cases by tumor location in the United States
- 8.4.3. Gender-specific Cases of UCC in the United States
- 8.4.4. Age-specific Cases of UCC in the United States
- 8.4.5. Mutation-specific Cases of UCC in the United States
- 8.4.6. Stage-specific Cases of UCC in the United States
- 8.4.7. Total treated Cases by line of therapy in the United States
- 8.5. EU4 and the UK
- 8.5.1. Total Incident Cases of UCC in EU4 and the UK
- 8.5.2. UCC Cases by tumor location in EU4 and the UK
- 8.5.3. Gender-specific Cases of UCC in EU4 and the UK
- 8.5.4. Age-specific Cases of UCC in EU4 and the UK
- 8.5.5. Mutation-specific Cases of UCC in EU4 and the UK
- 8.5.6. Stage-specific Cases of UCC in EU4 and the UK
- 8.5.7. Total treated Cases by line of therapy in EU4 and the UK
- 8.6. Japan
- 8.6.1. Total Incident Cases of UCC in Japan
- 8.6.2. UCC Cases by tumor location in Japan
- 8.6.3. Gender-specific Cases of UCC in Japan
- 8.6.4. Age-specific Cases of UCC in Japan
- 8.6.5. Mutation-specific Cases of UCC in Japan
- 8.6.6. Stage-specific Cases of UCC in Japan
- 8.6.7. Total treated Cases by line of therapy in Japan
- 9. KOL Views
- 10. Appendix
- 10.1. Acronyms and Abbreviations
- 10.2. Bibliography
- 10.3. Report Methodology
- 11. DelveInsight Capabilities
- 12. Disclaimer
- 13. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
